Roche Holding AG represents a strong commitment to innovation, integrity, and patient-centered healthcare. As one of the leading pharmaceutical and diagnostics companies globally, Roche focuses on developing groundbreaking therapeutic solutions and advanced diagnostic tools. The company's core values include scientific excellence, teamwork, and a passion for improving patients' lives. With a dedication to personalized healthcare and a long-standing tradition of ethical conduct, Roche strives to make a positive impact on society. Through continuous research and development efforts, Roche aims to provide effective treatments and diagnostic solutions for various diseases, ultimately contributing to the advancement of healthcare worldwide.

Roche Holding AG is primarily present in multiple countries and regions worldwide. The company has a significant presence in Switzerland, where it is headquartered. In addition, Roche Holding AG has a strong presence in the United States, Germany, Japan, China, and other key markets around the globe. With its global reach, Roche Holding AG has established itself as a leading biotechnology and pharmaceutical firm, delivering innovative healthcare solutions to diverse populations across various countries and regions.

Roche Holding AG has achieved numerous significant milestones throughout its history. Established in 1896, it has become a leader in the pharmaceutical and diagnostics industry. Some notable milestones include the development of groundbreaking drugs such as Valium, Tamiflu, and Herceptin, which have revolutionized the treatment of various diseases. Roche Holding AG has also been at the forefront of advancing precision medicine with its innovative therapies, such as Avastin and Rituxan. The company's commitment to research and development has resulted in a diverse product portfolio, contributing to its global success and recognition as a leading healthcare company.

Roche Holding AG, a renowned global healthcare company, has a rich history and background. Established in 1896 in Switzerland, Roche has become a leader in pharmaceuticals and diagnostics. With major breakthroughs in various therapeutic areas, Roche has contributed significantly to enhancing patient care and improving outcomes. The company's commitment to innovation and research has led to the development of groundbreaking medicines and diagnostic tests, addressing medical needs worldwide. Roche's diverse portfolio includes a range of medicines for oncology, immunology, neuroscience, infectious diseases, and more. With a strong focus on personalized healthcare, Roche continues to shape the future of medicine and positively impact patients' lives globally.

The main competitors of Roche Holding AG in the market include Novartis AG, Johnson & Johnson, and Pfizer Inc.

Roche Holding AG is primarily active in the pharmaceutical and healthcare industries.

The business model of Roche Holding AG is focused on pharmaceuticals and diagnostics. Roche is a global healthcare company that aims to improve people's lives by providing innovative medical solutions. With its innovative research and development capabilities, Roche develops and sells a wide range of pharmaceutical and biotechnology products. The company's diagnostics division specializes in developing and manufacturing diagnostic tests and systems to support personalized healthcare. Through ongoing investments in research, Roche strives to address unmet medical needs and improve patient outcomes. As a leading player in the healthcare industry, Roche is committed to delivering high-quality and effective healthcare solutions to individuals worldwide.

Roche Holding KGV ir 15,67.

Roche Holding KUV ir 3,32.

AlleAktien kvalitātes vērtējums Roche Holding ir 6/10.

gaidāmā Roche Holding apgrozījums ir 61,46 miljardi CHF.

gaidāmā Roche Holding peļņa ir 13,03 miljardi CHF.

The Roche Holding AG is a Swiss pharmaceutical company based in Basel. The company operates worldwide and specializes in the development and production of medications, as well as diagnostic and laboratory equipment. Roche is divided into two core business areas: pharmaceuticals and diagnostics. In the pharmaceuticals area, Roche specializes in the development of medications and therapies in the fields of oncology, immunology, virology, metabolic disorders, and CNS diseases. Some of Roche's most well-known medications include Avastin, Herceptin, MabThera, and Rituxan. These medications are used for the treatment of cancer and other serious diseases. In the diagnostics area, Roche holds a leading position in the field of in-vitro diagnostics (IVD) and offers tests and test systems for a variety of diseases. Roche is the world's largest provider of IVD tests and offers tests for the diagnosis of cancer, infectious diseases, blood clots, and cardiovascular diseases, among others. The company has also developed instruments and software to improve laboratory efficiency and accuracy. Roche has extensive expertise in medicine and the life sciences, and the company is committed to developing innovative therapies and solutions that improve healthcare. Roche's focus on research and development is evident - the company invests more than 11 billion Swiss francs annually in research and development projects and collaborates with leading research institutions. Roche's business model is focused on creating value for patients, customers, employees, and investors. The company places great importance on innovation, patient orientation, and sustainability, and is committed to protecting the environment and reducing CO2 emissions. Roche also pursues a targeted acquisition strategy to strengthen its presence in selected markets and acquire new technologies. In 2018, Roche acquired the US company Foundation Medicine, a leading company in the field of personalized oncology and diagnostics. With this acquisition, Roche strengthened its presence in the field of personalized medicine. Overall, Roche's business model is focused on long-term growth by developing innovative medications and diagnostic tests to meet the unmet need for healthcare services. The company is committed to improving healthcare worldwide and strives to ensure that patients can be treated faster and more effectively, and that diseases can be identified as early as possible.

Roche Holding izmaksā dividendes 9,30 CHF, kas tiek izmaksātas 1 reizes gadā.

Roche Holding izmaksā dividendes 1 reizes gadā.

Roche Holding ISIN ir CH0012032048.

Roche Holding WKN ir 855167.

Roche Holding simbols ir ROG.SW.

Pēdējo 12 mēnešu laikā Roche Holding maksāja dividendes 9,50 CHF apmērā. Tas atbilst aptuveni 3,74 % dividendes ražībai. Nākamajos 12 mēnešos Roche Holding plāno maksāt dividendes 11,25 CHF apmērā.

Roche Holding pašreizējā dividendu rentabilitāte ir 3,74 %.

Roche Holding maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos aprīlis, aprīlis, aprīlis, aprīlis.

Roche Holding pēdējo 37 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 11,25 CHF. Tas atbilst dividendes ražībai 4,43 %.

Roche Holding tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Roche Holding apmērā 9,6 CHF, kas tika izmaksāta 18.03.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 14.03.2024..

Pēdējās dividendes izmaksa notika 18.03.2024..

Gadā 2023, Roche Holding izmaksāja 9,3 CHF dividendes.

Roche Holding dividendes tiek izmaksātas CHF.